Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Recommendation of “Hold” by Analysts

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have been assigned an average recommendation of “Hold” from the seven analysts that are covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $4.94.

Several brokerages have weighed in on CARM. Baird R W cut Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, December 12th. Robert W. Baird downgraded shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $10.00 to $1.00 in a research note on Thursday, December 12th. BTIG Research lowered shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th. D. Boral Capital reaffirmed a “buy” rating and set a $12.00 target price on shares of Carisma Therapeutics in a report on Monday, January 13th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Carisma Therapeutics in a research report on Monday, December 16th.

Carisma Therapeutics Trading Down 0.5 %

CARM stock opened at $0.41 on Friday. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39. Carisma Therapeutics has a twelve month low of $0.38 and a twelve month high of $2.66. The company has a market cap of $17.27 million, a P/E ratio of -0.27 and a beta of 1.55. The business has a fifty day moving average of $0.45 and a 200-day moving average of $0.70.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Barclays PLC raised its holdings in Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after purchasing an additional 549,290 shares during the period. Renaissance Technologies LLC raised its stake in Carisma Therapeutics by 11.9% during the 4th quarter. Renaissance Technologies LLC now owns 231,357 shares of the company’s stock worth $97,000 after buying an additional 24,600 shares during the period. Finally, Wexford Capital LP raised its stake in Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after buying an additional 15,000 shares during the period. Institutional investors and hedge funds own 44.27% of the company’s stock.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.